167 related articles for article (PubMed ID: 37095262)
1. A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Hedenmalm K; Quinten C; Kurz X; Bradley M; Lee H; Eworuke E
Eur J Clin Pharmacol; 2023 Jun; 79(6):849-858. PubMed ID: 37095262
[TBL] [Abstract][Full Text] [Related]
2. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
[TBL] [Abstract][Full Text] [Related]
3. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
Cohen Sedgh R; Moon J; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
[TBL] [Abstract][Full Text] [Related]
4. Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany.
Rudolph UM; Enners S; Kieble M; Mahfoud F; Böhm M; Laufs U; Schulz M
J Hum Hypertens; 2021 Oct; 35(10):903-911. PubMed ID: 33057175
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
8. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Aiglova R; Taborsky M; Lazarova M; Pavlu L; Danek J; Precek J; Schee A; Gloger V; Cernicek V; Vicha M; Skala T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):322-327. PubMed ID: 34092792
[TBL] [Abstract][Full Text] [Related]
10. Current Status of Angiotensin Receptor Blocker Recalls.
Gunasekaran PM; Chertow GM; Bhalla V; Byrd JB
Hypertension; 2019 Dec; 74(6):1275-1278. PubMed ID: 31630573
[TBL] [Abstract][Full Text] [Related]
11. Impact of national valsartan recalls on Veterans' outcomes.
Morizio PL; Britnell SR; Ottman AA
Ther Adv Drug Saf; 2021; 12():20420986211016173. PubMed ID: 34249328
[TBL] [Abstract][Full Text] [Related]
12. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Dorosch T; Ganzer CA; Lin M; Seifan A
Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
[TBL] [Abstract][Full Text] [Related]
14. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
Hesse U; Godman B; Petzold M; Martin A; Malmström RE
Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Cohort Study of the 2018 Angiotensin Receptor Blocker Recalls and Subsequent Drug Shortages in Patients With Hypertension.
Devine JW; Tadrous M; Hernandez I; Callaway Kim K; Rothenberger SD; Mukhopadhyay N; Gellad WF; Suda KJ
J Am Heart Assoc; 2024 Jan; 13(1):e032266. PubMed ID: 38156554
[TBL] [Abstract][Full Text] [Related]
16. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
Vegter S; Nguyen NH; Visser ST; de Jong-van den Berg LT; Postma MJ; Boersma C
Am J Manag Care; 2011 Sep; 17(9):609-16. PubMed ID: 21902446
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Kim HS; Kim H; Lee SH; Kim JH
J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930
[TBL] [Abstract][Full Text] [Related]
18. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
[TBL] [Abstract][Full Text] [Related]
19. The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients.
Shin J; Kim HS; Min Kim T; Kim H; Lee SH; Hyoung Cho J; Lee H; Woo Yim H; Yoon KH
Basic Clin Pharmacol Toxicol; 2020 May; 126(5):424-431. PubMed ID: 31765038
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
